Hanmi's new amlodipine salt to get patent approval first in Korea.

Published: 2004-10-20 07:00:00

Updated: 2004-10-20 07:00:00

The patent for amlodpine camsylate, a new salt of amlodpine and anti-hypertension drug, (brand name: Amodipine) has been approved for the first time in Korea under the patent registration No. 0452491.

Amlodpine camsylate will be the first rival anti-hypertension drug against Norvasc, its orig...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK